Abstract 16455: Retrospective Multicenter Analysis for Smart and Luminexx Nitinol Stent Implantation for Superficial Femoral Artery Lesion (REAL-SL) Registry: 5 Years Experience
Objectives: We compared the patency of two types of nitinol stents in the superficial femoral artery (SFA) lesions as long as 5 years.
Background: Nitinol stents have shown superior long term patency to balloon angioplasty in the SFA. However, whether differences in patency exist among nitinol stents remains unkown.
Methods: We retrospectively analyzed the prospectively maintained multicenter database that included consecutive 511 patients who underwent endovascular therapy (EVT) for de-novo SFA lesions with provisional stenting: either with Smart (S, n=503) or with Luminexx (L, n=135) stents, in 638 limbs. Primary endpoint comprised the vessel patency defined as the peak systolic velocity ratio <2.4 by Doppler ultrasound, or by angiography (% diameter stenosis <50%). Patients were followed for 18+/−13 months. Outcomes were compared between Smart and Luminexx with Kaplan-Meier and log-rank methods. Propensity-matched analysis was additionally performed.
Results: Stent fracture was observed 11% (57/503) in S, and 23% (135/638) in L (P=0.0005). Despite the higher prevalence of chronic total occlusion (55% versus 40%, p=0.002), and the longer lesion length (154±93mm versus 135±71mm, p=0.03) in S, patency was similar as long as 5 years. With propensity-matched analysis in 119 lesions, patency for 5 years was 67% in S, and 64% in L (p=0.33).
Conclusions: Although stent fracture rate was higher in L, the two types of nitinol stents demonstrated similar patency as long as 5 years.
- © 2010 by American Heart Association, Inc.